Eye, Published online: 29 September 2026; doi:10.1038/s41433-026-04947-7Outcomes of switching from faricimab to aflibercept 8 mg in nAMD: a real-world case series

Kodiak Sciences informó el 28 de septiembre de 2026 que sus dos tratamientos experimentales para la degeneración macular húmeda relacionada con la edad cumplieron el objetivo principal del ensayo DAYBREAK de fase 3. Zenkuda y KSI-501 lograron resultados de agudeza visual no inferiores a los de Eylea (aflibercept) al cabo de aproximadamente un año, según los resultados iniciales difundidos por la empresa. Las acciones de Kodiak cerraron ese lunes con una subida de casi 178%, mientras la compañía prepara una solicitud de aprobación para Zenkuda en Estados Unidos. ## El intervalo de seis meses se alcanzó en 54% de los tratados con Zenkuda La cifra que puede cambiar la frecuencia de las inyecciones corresponde a Zenkuda: 54% de quienes lo recibieron alcanzó un intervalo de seis meses entre dosis al primer año, de acuerdo con Kodiak. El tratamiento comenzó con cuatro dosis mensuales y después se ajustó entre cuatro y 24 semanas según la presencia de líquido en la retina. Eso no significa que todos los pacientes puedan pasar medio año sin una nueva inyección. DAYBREAK comparó por separado Zenkuda y KSI-501 con un grupo de referencia tratado con aflibercept. Ambos brazos experimentales cumplieron el criterio de no inferioridad en visión; ese resultado indica que alcanzaron el margen fijado por el ensayo frente al comparador, pero no demuestra que mejoren más la vista. KSI-501 también actúa sobre la interleucina 6, relacionada con procesos inflamatorios, además de bloquear VEGF. Kodiak planea analizar si ciertos grupos de pacientes obtienen un beneficio adicional de ese mecanismo. La enfermedad afecta la visión central. El Instituto Nacional del Ojo de Estados Unidos explica que los tratamientos anti-VEGF suelen requerir inyecciones repetidas. Por eso, el intervalo observado con Zenkuda puede importar para la carga de tratamiento. El 54% describe lo ocurrido dentro del ensayo durante el primer año; no permite predecir qué proporción podrá mantener esa pauta en la práctica clínica. ## La solicitud regulatoria aún está pendiente Kodiak planea presentar ante la FDA una solicitud de licencia biológica para Zenkuda en el cuarto trimestre de 2026, apoyada en cinco ensayos de fase 3 para tres enfermedades de la retina. La compañía comunicó resultados iniciales de DAYBREAK; presentar la solicitud y obtener autorización son pasos distintos. Ni Zenkuda ni KSI-501 están aprobados para su comercialización. El mercado reaccionó antes de esa revisión: las acciones de Kodiak terminaron la sesión del 28 de septiembre en 89.92 dólares, un avance de 177.96% frente al cierre previo, según Stock Analysis. La cifra bursátil mide la reacción de los inversionistas al anuncio, mientras que el posible cambio para los pacientes depende de la evaluación regulatoria de la eficacia, seguridad y pauta de dosificación. _Fuentes:_ 1, 2, 3

Kodiak Sciences announced that Zenkuda and tabirafusp-ted achieved noninferiority to Regeneron's aflibercept in vision gains in the Phase 3 DAYBREAK study for wet age-related macular degeneration. Zenkuda showed durability allowing over half of patients to reach six-month dosing intervals, and Kodiak plans to file a biologics license application in late 2026 covering three retinal disease indications.

Editor’s note: This is a developing news story. Please check back soon for updates. Two investigational agents from Kodiak Sciences helped improve vision in patients with wet age-related macular degeneration, according to a press release. In the phase 3 DAYBREAK study, researchers assessed Zenkuda (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer) vs. Eylea (aflibercept, Regeneron) in patients wet AMD. Zenkuda is an anti-VEGF that uses Kodiak’s antibody biopolymer conjugate (ABC) platform and is designed to maintain more durable drug levels. KSI-501 is an anti-IL-6, VEGF-trap

Editor’s note: This is a developing news story. Please check back soon for updates. Two investigational agents from Kodiak Sciences helped improve vision in patients with wet age-related macular degeneration, according to a press release. In the phase 3 DAYBREAK study, researchers assessed Zenkuda (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer) vs. Eylea (aflibercept, Regeneron) in patients wet AMD. Zenkuda is an anti-VEGF that uses Kodiak’s antibody biopolymer conjugate (ABC) platform and is designed to maintain more durable drug levels. KSI-501 is an anti-IL-6, VEGF-trap

.

OCT helps identify the risk of exudative recurrence after regression in patients with polypoidal choroidal vasculopathy.

Eye, Published online: 21 September 2026; doi:10.1038/s41433-026-04864-9Clustered sterile intraocular inflammation following intravitreal aflibercept injections: involvement of 2 mg, 8 mg, and biosimilar formulations

These findings may help inform clinical monitoring for patients receiving E8 for nAMD

Eye, Published online: 14 September 2026; doi:10.1038/s41433-026-04863-wComment on: ‘Aflibercept 8 mg in neovascular age-related macular degeneration and diabetic macular oedema’

In this context, this study will provide a qualitative exploration of the personal perception and experiences of AMD patients treated with anti-VEGF.

Holz et al1 present the ANDROMEDA study, a prospective multicenter investigation evaluating adherence to intravitreal aflibercept therapy in patients with neovascular age-related macular degeneration (nAMD) over 24 months.1 The study provides valuable prospective trustable data on treatment adherence and identifies several patient- and system-level factors associated with deviations from recommended treatment schedules. As long-term anti-VEGF therapy remains central to nAMD management, understanding adherence dynamics in routine practice is clinically important.

Polypoidal choroidal vasculopathy (PCV) is characterized by polypoidal lesions (PLs) arising from a branching neovascular network (BNN).1,2 Due to its propensity to leak and bleed, closure of the PL(s) has been considered an important anatomical endpoint in the treatment of PCV, in addition to reduction in exudation, which is measured with central retinal thickness.3,4 However, the effect of treatment on the BNN remains unclear. Some previous indocyanine green angiography (ICGA) based studies suggest that treatment has limited effect on the BNN.

Results of a registry analysis on the real-world use of aflibercept 8 mg in treatment-naive and previously treated eyes with diabetic macular edema were presented at the American Society of Retina Specialists annual meeting. “This is a registry study [on Eylea HD (aflibercept 8 mg, Regeneron)], so we don’t have individual patient-level data, and unfortunately, at this time, we don’t have the ability to look at the OCTs, but this, to me, is quite helpful in my day-to-day decision-making” Sunir J. Garg, MD, FACS, FASRS, chief of the retina service at Wills Eye Hospital and professor of

On August 3, 2026, Biocon Limited announced the commercial launch of its biosimilar YESAFILI (aflibercept-jbvf) in the United States. YESAFILI is...

On August 3, 2026, Biocon Limited announced the commercial launch of its biosimilar YESAFILI (aflibercept-jbvf) in the United States. YESAFILI is...

Aim To indirectly evaluate the comparative efficacy and safety of aflibercept 8 mg and faricimab in treating retinal vein occlusion (RVO)-associated macular oedema.Methods We searched MEDLINE, Embase and Cochrane CENTRAL from inception to 11 December 2025. We performed frequentist network meta-analysis on efficacy and safety outcomes at loading phase completion (24–40 weeks), with 4 weekly aflibercept 2 mg as the common comparator.Results Three trials with 2174 adults were included. 8 weekly aflibercept 8 mg with five 4 weekly loading doses was more likely to achieve a best corrected visual acuity (BCVA) of ≥69 letters (Snellen 20/40, unconditional driving threshold) compared with 4 weekly faricimab (risk ratio (RR) 1.18, 95% CI 1.03 to 1.35). 4 weekly faricimab demonstrated greater rates of complete resolution of intraretinal and subretinal fluid against 8 weekly aflibercept 8 mg with both five and three 4 weekly loading doses (both RR 1.12, 95% CI 1.01 to 1.25). There was no evidence of a difference in mean BCVA improvement between agents. Both aflibercept 8 mg and 2 mg regimens were associated with a greater risk of clinically significant intraocular pressure (IOP) rise of 30–60 min post-injection compared with 4 weekly faricimab (8 weekly aflibercept 8 mg with five 4 weekly loading doses, RR 6.42, 95% CI 1.85 to 22.34; 8 weekly aflibercept 8 mg with three 4 weekly loading doses, RR 6.97, 95% CI 2.02 to 24.08; 4 weekly aflibercept 2 mg, RR 2.12, 95% CI 1.01 to 4.47).Conclusion Aflibercept 8 mg and faricimab show comparable overall visual efficacy for RVO-associated macular oedema. Indirect comparisons suggest aflibercept 8 mg may increase the probability of achieving driving vision, while faricimab may offer greater anatomical drying and a lower risk of acute IOP elevation.PROSPERO registration number CRD420251249785.